The short version
Just 3 companies supply this market — thin enough that a single exit would be felt immediately.
Market view
adalimumab-atto
30 marketed package NDCs · 3 active manufacturers
Most dispensed: ADALIMUMAB 40 mg/.4mL · Injection · #2 syringes/carton / .4 ml in 1 syringe · ADALIMUMAB 40 mg/.4mL · Injection · #1 syringe/carton / .4 ml in 1 syringe · ADALIMUMAB 40 mg/.8mL · Injection · #1 syringe/carton / .8 ml in 1 syringe · ADALIMUMAB 80 mg/.8mL · Injection · #2 syringes/carton / .8 ml in 1 syringe
Same drug class
Other molecules FDA puts in Tumor Necrosis Factor Blocker, with whether each is in shortage right now. Same class is not the same drug — substitution is a clinical decision, and this is a supply picture, not a recommendation.
Common questions
- Is Adalimumab-atto in shortage right now?
- No. FDA does not currently list Adalimumab-atto in shortage. This page is rebuilt every morning from FDA's shortage database, so a new posting appears here the day it is published.
- Who makes Adalimumab-atto?
- 3 companies have marketed Adalimumab-atto in the last 30 days, according to the FDA NDC Directory. That is a thin market — if one stops making it, supply is at risk quickly. Every manufacturer and package is listed on this page.
All marketed products
Expand a strength to see its dosage forms, then package sizes, then each manufacturer and NDC. Click an NDC for its full detail page.